434 related articles for article (PubMed ID: 33231464)
1. pH-Sensitive Nanodrug Carriers for Codelivery of ERK Inhibitor and Gemcitabine Enhance the Inhibition of Tumor Growth in Pancreatic Cancer.
Ray P; Dutta D; Haque I; Nair G; Mohammed J; Parmer M; Kale N; Orr M; Jain P; Banerjee S; Reindl KM; Mallik S; Kambhampati S; Banerjee SK; Quadir M
Mol Pharm; 2021 Jan; 18(1):87-100. PubMed ID: 33231464
[TBL] [Abstract][Full Text] [Related]
2. pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant K-Ras-addicted pancreatic cancer cells and mouse model.
Dutta D; Ray P; De A; Ghosh A; Hazra RS; Ghosh P; Banerjee S; Diaz FJ; Upadhyay SP; Quadir M; Banerjee SK
PLoS One; 2024; 19(4):e0297749. PubMed ID: 38687749
[TBL] [Abstract][Full Text] [Related]
3. PEG-b-poly (carbonate)-derived nanocarrier platform with pH-responsive properties for pancreatic cancer combination therapy.
Ray P; Confeld M; Borowicz P; Wang T; Mallik S; Quadir M
Colloids Surf B Biointerfaces; 2019 Feb; 174():126-135. PubMed ID: 30447521
[TBL] [Abstract][Full Text] [Related]
4. Co-delivery of autophagy inhibitor and gemcitabine using a pH-activatable core-shell nanobomb inhibits pancreatic cancer progression and metastasis.
Chen X; Tao Y; He M; Deng M; Guo R; Sheng Q; Wang X; Ren K; Li T; He X; Zang S; Zhang Z; Li M; He Q
Theranostics; 2021; 11(18):8692-8705. PubMed ID: 34522207
[No Abstract] [Full Text] [Related]
5. Micelle Mixtures for Coadministration of Gemcitabine and GDC-0449 To Treat Pancreatic Cancer.
Karaca M; Dutta R; Ozsoy Y; Mahato RI
Mol Pharm; 2016 Jun; 13(6):1822-32. PubMed ID: 26981724
[TBL] [Abstract][Full Text] [Related]
6. Self-Assembled Gemcitabine Prodrug Nanoparticles Show Enhanced Efficacy against Patient-Derived Pancreatic Ductal Adenocarcinoma.
Wu L; Zhang F; Chen X; Wan J; Wang Y; Li T; Wang H
ACS Appl Mater Interfaces; 2020 Jan; 12(3):3327-3340. PubMed ID: 31872760
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
[TBL] [Abstract][Full Text] [Related]
8. Dendritic Polyglycerol-Derived Nano-Architectures as Delivery Platforms of Gemcitabine for Pancreatic Cancer.
Ray P; Ferraro M; Haag R; Quadir M
Macromol Biosci; 2019 Jul; 19(7):e1900073. PubMed ID: 31183964
[TBL] [Abstract][Full Text] [Related]
9. Oral Delivery of Photopolymerizable Nanogels Loaded with Gemcitabine for Pancreatic Cancer Therapy: Formulation Design, and in vitro and in vivo Evaluations.
Yugatama A; Huang YL; Hsu MJ; Lin JP; Chao FC; Lam JKW; Hsieh CM
Int J Nanomedicine; 2024; 19():3753-3772. PubMed ID: 38686338
[TBL] [Abstract][Full Text] [Related]
10. Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer.
Awasthi N; Kronenberger D; Stefaniak A; Hassan MS; von Holzen U; Schwarz MA; Schwarz RE
Cancer Lett; 2019 Sep; 459():41-49. PubMed ID: 31153980
[TBL] [Abstract][Full Text] [Related]
11. TRIM29 facilitates gemcitabine resistance via MEK/ERK pathway and is modulated by circRPS29/miR-770-5p axis in PDAC.
Huang W; Hu X; He X; Pan D; Huang Z; Gu Z; Huang G; Wang P; Cui C; Fan Y
Drug Resist Updat; 2024 May; 74():101079. PubMed ID: 38518727
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of Pancreatic Cancer Therapy Efficacy by Type-1 Matrix Metalloproteinase-Functionalized Nanoparticles for the Selective Delivery of Gemcitabine and Erlotinib.
Yin N; Yu H; Zhang X; Lv X
Drug Des Devel Ther; 2020; 14():4465-4475. PubMed ID: 33122890
[TBL] [Abstract][Full Text] [Related]
13. Effective encapsulation and biological activity of phosphorylated chemotherapeutics in calcium phosphosilicate nanoparticles for the treatment of pancreatic cancer.
Loc WS; Linton SS; Wilczynski ZR; Matters GL; McGovern CO; Abraham T; Fox T; Gigliotti CM; Tang X; Tabakovic A; Martin JA; Clawson GA; Smith JP; Butler PJ; Kester M; Adair JH
Nanomedicine; 2017 Oct; 13(7):2313-2324. PubMed ID: 28673852
[TBL] [Abstract][Full Text] [Related]
14. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
Awasthi N; Zhang C; Hinz S; Schwarz MA; Schwarz RE
J Exp Clin Cancer Res; 2013 Mar; 32(1):12. PubMed ID: 23497499
[TBL] [Abstract][Full Text] [Related]
15. OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo.
Zhi X; Chen W; Xue F; Liang C; Chen BW; Zhou Y; Wen L; Hu L; Shen J; Bai X; Liang T
Oncotarget; 2015 Sep; 6(28):26230-41. PubMed ID: 26213847
[TBL] [Abstract][Full Text] [Related]
16. Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer.
Awasthi N; Schwarz MA; Schwarz RE
HPB (Oxford); 2011 Sep; 13(9):597-604. PubMed ID: 21843259
[TBL] [Abstract][Full Text] [Related]
17. Co-delivery of microRNA-21 antisense oligonucleotides and gemcitabine using nanomedicine for pancreatic cancer therapy.
Li Y; Chen Y; Li J; Zhang Z; Huang C; Lian G; Yang K; Chen S; Lin Y; Wang L; Huang K; Zeng L
Cancer Sci; 2017 Jul; 108(7):1493-1503. PubMed ID: 28444967
[TBL] [Abstract][Full Text] [Related]
18. Dual Enzymatic Reaction-Assisted Gemcitabine Delivery Systems for Programmed Pancreatic Cancer Therapy.
Han H; Valdepérez D; Jin Q; Yang B; Li Z; Wu Y; Pelaz B; Parak WJ; Ji J
ACS Nano; 2017 Feb; 11(2):1281-1291. PubMed ID: 28071891
[TBL] [Abstract][Full Text] [Related]
19. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
[TBL] [Abstract][Full Text] [Related]
20. Precise engineering of hybrid molecules-loaded macromolecular nanoparticles shows
Liu D; Zhang W; Liu X; Qiu R
Drug Deliv; 2021 Dec; 28(1):776-786. PubMed ID: 33866910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
